IMPACT BIOMEDICAL INC
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
IBO$4.33+5.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
**Impact BioMedical, Inc. and Subsidiaries **
| 2023 · 2022 | |||
|---|---|---|---|
| Revenue: | $ | - | $50,000 |
| Costs and expenses: | |||
| Selling, general and administrative (including stock-based compensation) | 315,000 | 325,000 | |
| Amortization | 1,120,000 | 1,113,000 | |
| Professional Services | 1,262,000 | 722,000 | |
| Research & Development | 1,147,000 | 1,226,000 | |
| Other General Expenses | 184,000 | 68,000 | |
| Total costs and expenses | 4,028,000 | 3,454,000 | |
| Operating loss | (4,028,000) | (3,404,000) | |
| Other income (expense): | |||
| Interest income | 13,000 | 24,000 | |
| Other income | 52,000 | 66,000 | |
| Interest expense | (444,000) | (462,000) | |
| Impairment of investment | - | (4,100,000) | |
| Loss from operations before income taxes | (4,407,000) | (7,876,000) | |
| Income tax benefit | - | 621,000 | |
| Net loss | (4,407,000) | (7,255,000) | |
| Loss from operations attributed to noncontrolling interest | 71,000 | 204,000 | |
| Net loss attributable to common stockholders | (4,336,000) | (7,051,000) | |
| Loss per common share: | |||
| Basic | $(0.07) | $(0.10) | |
| Diluted | $(0.07) | $(0.10) | |
| Shares used in computing loss per common share: | |||
| Basic | 60,248,078 | 70,496,041 | |
| Diluted | 60,248,078 | 70,496,041 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.